News | Hypertension | January 04, 2016

Positive Results for New Oral Drug for Pulmonary Hypertension

Largest study ever shows effectiveness of first orally available selective prostacyclin IP receptor agonist

January 4, 2016 — Living with pulmonary arterial hypertension (PH) is challenging, but the chore of treating the rare heart disease may change following promising clinical trial data published in the Dec. 24 issue of the New England Journal of Medicine.

Data from the largest study ever of pulmonary hypertension shows the oral medication Selexipag led to a 40 percent reduction in hospitalizations and worsening symptoms among patients with pulmonary hypertension.

Selexipag targets a well-known disease pathway that opens blood vessels to the lungs and improves heart function and is easier to use than PH treatments delivered with infusions or injections.

“For more than two decades we’ve targeted the prostacyclin pathway to induce vasodilation in these blood vessels in the lung,” said senior study author Vallerie McLaughlin, M.D., director of the University of Michigan Pulmonary Hypertension Program.

“But because of the cumbersome nature of treatment, patients would often wait until late stages to begin therapy. Having an oral medication to attack the disease pathway will be a major advancement because less ill patients will be willing to begin this therapy,” McLaughlin said.

Selexipag demonstrated effectiveness while its most frequent adverse events were headache, diarrhea, nausea, muscle pain and joint pain. The side effects were considered consistent with prostacyclin therapy.

The medication is not commercially available. Following the phase 3 clinical trial, the U.S. Food and Drug Administration is evaluating the drug.

Pulmonary hypertension, which is high blood pressure in the loop of blood vessels connecting the heart and lungs, can make everyday activities exhausting. It often leads to life-threatening heart failure as the heart works harder to pump blood to the lungs.

The greatest number of cases is reported in women between ages 21 and 40 who most often experience fatigue and shortness of breath.

While a rare disease, research of causes and treatment of pulmonary hypertension is growing. The GRIPHON study is a standout because of its size and scope, enrolling 1,156 patients with pulmonary hypertension from 181 centers from 39 countries in North and South America, Europe, Asia-Pacific and Africa.

Collaborators from the U.S. and Europe led the GRIPHON study, which was sponsored by Actelion Pharmaceuticals.

McLaughlin is a consultant to Actelion and served on the steering committee for the GRIPHON study.

For more information: www.med.umich.edu


Related Content

News | Hypertension

May 19, 2025 — Gradient Denervation Technologies recently announced the company’s pulmonary denervation system has ...

Home May 20, 2025
Home
News | Hypertension

April 9, 2025 — Idorsia Ltd recently announced that the US Food & Drug Administration (FDA), after having released ...

Home April 09, 2025
Home
News | Hypertension

Mar. 10, 2025-- Corcept Therapeutics Inc., a commercial-stage company engaged in the discovery and development of ...

Home March 11, 2025
Home
News | Hypertension

Jan. 9, 2025 — Gender-based racism through microaggressions may be linked to higher blood pressure postpartum and beyond ...

Home January 14, 2025
Home
News | Hypertension

Jan. 8, 2025 — Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing medicines ...

Home January 08, 2025
Home
News | Hypertension

Dec. 11, 2024 — Older adults whose blood pressure fluctuates over time may be more likely to have problems with thinking ...

Home December 19, 2024
Home
News | Hypertension

June 28, 2024 — AstraZeneca has set out a new ambition for Healthy Heart Africa, its flagship health equity initiative ...

Home June 28, 2024
Home
News | Hypertension

June 6, 2024 — A substantial portion of young athletes are at risk of hypertension, according to a study presented at ...

Home June 06, 2024
Home
News | Hypertension

May 16, 2024 — People were more likely to develop a type of treatment-resistant hypertension when they experienced ...

Home May 16, 2024
Home
News | Hypertension

May 8, 2024 — Ultrasound could one day complement or even replace drugs to treat diseases. Bioelectronic medicine ...

Home May 08, 2024
Home
Subscribe Now